HOLX Quote, Financials, Valuation and Earnings

Bio-Rad Laboratories has a net margin of -1.73% compared to Hologic's net margin of 10.93%. Hologic's return on equity of 11.45% beat Bio-Rad Laboratories's return on equity of -29.59%.

Hologic has a consensus price target of $67.27, signalling upside risk potential of 3.77%. On the other hand Bio-Rad Laboratories has an analysts' consensus of $314.33 which suggests that it could grow by 32.12%. Given that Bio-Rad Laboratories has higher upside potential than Hologic, analysts believe Bio-Rad Laboratories is more attractive than Hologic.

Hologic has a beta of 0.549, which suggesting that the stock is 45.069% less volatile than S&P 500. In comparison Bio-Rad Laboratories has a beta of 0.932, suggesting its less volatile than the S&P 500 by 6.799%.

Hologic has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bio-Rad Laboratories offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hologic pays -- of its earnings as a dividend. Bio-Rad Laboratories pays out -- of its earnings as a dividend.

Hologic quarterly revenues are $1B, which are larger than Bio-Rad Laboratories quarterly revenues of $585.4M. Hologic's net income of -$17.4M is lower than Bio-Rad Laboratories's net income of $64M. Notably, Hologic's price-to-earnings ratio is 27.35x while Bio-Rad Laboratories's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hologic is 3.74x versus 2.63x for Bio-Rad Laboratories. Usually stocks with elevated PS ratios are considered overvalued.

Nuwellis has a net margin of -1.73% compared to Hologic's net margin of -158.3%. Hologic's return on equity of 11.45% beat Nuwellis's return on equity of -670.55%.

Hologic has a consensus price target of $67.27, signalling upside risk potential of 3.77%. On the other hand Nuwellis has an analysts' consensus of $13.00 which suggests that it could grow by 3975.58%. Given that Nuwellis has higher upside potential than Hologic, analysts believe Nuwellis is more attractive than Hologic.

Hologic has a beta of 0.549, which suggesting that the stock is 45.069% less volatile than S&P 500. In comparison Nuwellis has a beta of 0.483, suggesting its less volatile than the S&P 500 by 51.723%.

Hologic has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nuwellis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hologic pays -- of its earnings as a dividend. Nuwellis pays out -- of its earnings as a dividend.

Hologic quarterly revenues are $1B, which are larger than Nuwellis quarterly revenues of $1.9M. Hologic's net income of -$17.4M is lower than Nuwellis's net income of -$3M. Notably, Hologic's price-to-earnings ratio is 27.35x while Nuwellis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hologic is 3.74x versus 0.08x for Nuwellis. Usually stocks with elevated PS ratios are considered overvalued.

Quanterix has a net margin of -1.73% compared to Hologic's net margin of -67.73%. Hologic's return on equity of 11.45% beat Quanterix's return on equity of -14.39%.

Hologic has a consensus price target of $67.27, signalling upside risk potential of 3.77%. On the other hand Quanterix has an analysts' consensus of $11.25 which suggests that it could grow by 90.68%. Given that Quanterix has higher upside potential than Hologic, analysts believe Quanterix is more attractive than Hologic.

Hologic has a beta of 0.549, which suggesting that the stock is 45.069% less volatile than S&P 500. In comparison Quanterix has a beta of 1.055, suggesting its more volatile than the S&P 500 by 5.534%.

Hologic has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quanterix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hologic pays -- of its earnings as a dividend. Quanterix pays out -- of its earnings as a dividend.

Hologic quarterly revenues are $1B, which are larger than Quanterix quarterly revenues of $30.3M. Hologic's net income of -$17.4M is higher than Quanterix's net income of -$20.5M. Notably, Hologic's price-to-earnings ratio is 27.35x while Quanterix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hologic is 3.74x versus 1.70x for Quanterix. Usually stocks with elevated PS ratios are considered overvalued.

Varex Imaging has a net margin of -1.73% compared to Hologic's net margin of 3.24%. Hologic's return on equity of 11.45% beat Varex Imaging's return on equity of -7.36%.

Hologic has a consensus price target of $67.27, signalling upside risk potential of 3.77%. On the other hand Varex Imaging has an analysts' consensus of $16.60 which suggests that it could grow by 114.19%. Given that Varex Imaging has higher upside potential than Hologic, analysts believe Varex Imaging is more attractive than Hologic.

Hologic has a beta of 0.549, which suggesting that the stock is 45.069% less volatile than S&P 500. In comparison Varex Imaging has a beta of 0.657, suggesting its less volatile than the S&P 500 by 34.323%.

Hologic has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Varex Imaging offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hologic pays -- of its earnings as a dividend. Varex Imaging pays out -- of its earnings as a dividend.

Hologic quarterly revenues are $1B, which are larger than Varex Imaging quarterly revenues of $212.9M. Hologic's net income of -$17.4M is lower than Varex Imaging's net income of $6.9M. Notably, Hologic's price-to-earnings ratio is 27.35x while Varex Imaging's PE ratio is 17.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hologic is 3.74x versus 0.41x for Varex Imaging. Usually stocks with elevated PS ratios are considered overvalued.